Ponzin Diego, Fasolo Adriano, Montani Giancarlo, Bazzocchi Daniele
The Veneto Eye Bank Foundation, Venice, Italy.
Dipartimento di Matematica e Fisica, Centro di Ricerca in Contattologia Avanzata, University of Salento, Lecce, Italy.
Ophthalmol Ther. 2025 Jul 3. doi: 10.1007/s40123-025-01195-y.
Myopia is a growing public health concern, particularly among young individuals. Several pharmacological and optical interventions exist to slow its progression, yet each has limitations. In January 2021, Safilens introduced the Delivery Tyro daily disposable contact lens, which releases hyaluronic acid, tamarind seed polysaccharide, and tyrosine, a dopamine precursor with antioxidative and cytoprotective properties.
This study analyzed post-market surveillance data collected by 55 optometrists from 241 myopic subjects (mean age, 14.73 years; mean initial spherical equivalent (SE) refraction, - 2.72 diopters [D]) over a 12-month period of bilateral Delivery Tyro lens use. The purpose of the analysis was to compare the observed myopia progression in Delivery Tyro users with expected rates based on control SE refraction data derived from meta-analyses of similar age and ethnic cohorts.
Delivery Tyro users experienced slower rates of myopia progression than expected. After 12 months of lens wear, the average change in SE was a - 0.04 D compared with the expected change of - 0.28 D from the reference control group (P < 0.001). Furthermore, 94% of eyes exhibited no significant change in SE (defined as a change of - 0.25 D or less).
These findings support the hypothesis that Delivery Tyro may reduce myopia progression, likely attributable to the release of tyrosine during lens wear, either due to its antioxidative properties or its role as a precursor of dopamine, a key neurotransmitter in the retina involved in visual signaling, and refractive development. Given the convenience of daily disposable lenses, Delivery Tyro may offer a practical solution for myopia management, particularly for young patients at elevated risk of rapid myopia progression due to genetic and environmental factors. Further confirmation of the efficacy of Delivery Tyro through controlled, randomized clinical trials is warranted.
近视日益成为一个公共卫生问题，尤其是在年轻人中。目前有多种药物和光学干预措施可减缓近视进展，但每种方法都有局限性。2021年1月，Safilens推出了Delivery Tyro日抛型隐形眼镜，该镜片可释放透明质酸、罗望子种子多糖和酪氨酸，酪氨酸是一种具有抗氧化和细胞保护特性的多巴胺前体。
本研究分析了55位验光师收集的241名近视患者（平均年龄14.73岁；平均初始球镜等效（SE）屈光度为-2.72D）在双侧佩戴Delivery Tyro镜片12个月期间的上市后监测数据。分析目的是将Delivery Tyro使用者观察到的近视进展情况与基于类似年龄和种族队列的荟萃分析得出的对照SE屈光度数据的预期进展率进行比较。
Delivery Tyro使用者的近视进展速度比预期慢。佩戴镜片12个月后，SE的平均变化为-0.04D，而参考对照组的预期变化为-0.28D（P<0.001）。此外，94%的眼睛SE无显著变化（定义为变化-0.25D或更小）。
这些发现支持了Delivery Tyro可能降低近视进展的假设，这可能归因于镜片佩戴期间酪氨酸的释放，这可能是由于其抗氧化特性，或者是因为它作为多巴胺的前体，多巴胺是视网膜中参与视觉信号传导和屈光发育的关键神经递质。鉴于日抛型镜片的便利性，Delivery Tyro可能为近视管理提供一种实用的解决方案，特别是对于因遗传和环境因素而近视快速进展风险较高的年轻患者。有必要通过对照的随机临床试验进一步证实Delivery Tyro的疗效。
